BC Innovations | Nov 6, 2017
Distillery Therapeutics


INDICATION: Pain Mouse studies suggest endosome-targeting conjugates of CRLR and NK1R antagonists could help treat chronic pain. The conjugates were created by linking CRLR and NK1R antagonist tool compounds to the lipid cholestanol, which targets...
BC Innovations | May 23, 2013
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Adrenomedullin (ADM; AM) and calcitonin receptor-like (CRLR; CALCRL) levels to diagnose preeclampsia Mouse studies suggest monitoring levels of ADM or its receptor, CRLR, could enable early...
BC Innovations | May 23, 2013
Tools & Techniques

Revisiting adrenomedullin in preeclampsia

A North Carolina team has shown that fetal deficiency in adrenomedullin resulted in mouse placental abnormalities similar to those found in preeclampsia, thereby underscoring adrenomedullin's potential as a marker for the indication. 1 Future studies...
BC Innovations | Jan 24, 2013
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Clostridium Calcitonin receptor-like (CALCRL; CRLR) Rat studies suggest decreasing CRLR expression in the intestines could help treat Clostridium difficile infection....
BioCentury | Jan 31, 2011
Emerging Company Profile

Medella: RAMPing up

While adrenomedullin has been implicated in the progression of cancer, it was abandoned by pharma years ago due to safety problems stemming from a poor understanding of the target's biology. Medella Therapeutics Ltd. believes it...
Items per page:
1 - 5 of 5